Video

Dr. Trinh on the Impact of the COVID-19 Pandemic on Prostate Cancer

Quoc-Dien Trinh, MD, discusses the impact of the coronavirus disease 2019 pandemic on prostate cancer.

Quoc-Dien Trinh, MD, an associate professor of surgery at Harvard Medical School; co-director of the Dana-Farber/Brigham and Women's Prostate Cancer Center; and director of the Ambulatory Clinical Operations in the Division of Urological Surgery at Brigham and Women’s Hospital, discusses the impact of the coronavirus disease 2019 (COVID-19) pandemic on prostate cancer.

Historically, prostate cancer has been a complex disease, says Trinh​. Moreover, the COVID-19 pandemic has amplified this complexity.

Among patients who are scheduled to undergo surgery, it is necessary to weigh the risks and benefits of the intervention before any final decisions are made, ​Trinh explains.

For example, high-risk patients ​could be offer​ed alternative treatment, such as neoadjuvant androgen deprivation therapy, Trinh concludes.

Related Videos
Byoung Chol Cho, MD, PhD, professor, internal medicine, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine
Stephen J. Freedland, MD
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic